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Background: Arteriovenous fistula (AVF) has better rate of patency and lower rate of complication 
compared to other vascular access for hemodialysis. One priority to be concerned is access failure for 
hemodialysis access is common findings and correspond with high healthcare cost, morbidity and 
mortality.
Objective: This case report aimed to elaborate the proper management of patient with arterio fistula 
stenosis.
Case Illustration: A man, 64 years old, stage V CKD with AVF in his left arm for hemodialysis access was 
admitted to our hospital due to difficulty in cannulation during his last hemodialysis. He had AVF For 
Hemodialysis access for two years. About 1 month before, he undergone surgery for creation of AVF for 
hemodialysis access in his right arm, but AVF was failed to reach maturation. Based on vascular doppler 
ultrasound (DUS) done in AVF of the left arm revealed there was stenosis in the juxta-anastomosis site 
and cephalic venous stenosis. Angioplasty was done in anastomose AVF and implantation of venous stent 
in the left cephalic vein.
Conclusion: For patients on hemodialysis, vascular access is considered as the lifeline. Complications 
related to Vascular access is associated with morbidity and reduced quality of life. Surgery often difficult 
to do as readily as a percutaneous approach. In more than 80% of hemodialysis access underwent 
percutaneous interventions, flow was successfully restored. Based on this success rate, it has replaced 





 Complications related to vascular access is associated with 
morbidity and reduced quality of life. the main problem for patients 
undergoing hemodialysis is dysfunction of hemodialysis access. The 
common cause of this is venous stenosis. The site AVF tend to develop 
stenosis is at the juxta-anastomosis site and the outflow vein. The first 
line management of AVF stenosis is balloon angioplasty, with stent 
placement is only done is special circumstances.
2. Case Illustration
 A 64 years old man with stage V CKD with AVF in his left arm 
for hemodialysis access was admitted to our hospital due to difficulty in 
cannulation during his last hemodialysis. He had AVF For Hemodialysis 
access since two years ago. About 1 month before, he undergone 
surgery for creation of AVF for hemodialysis access in his right arm, but 
AVF was failed to reach maturation. Based on vascular ultrasound done 
in AVF of the left arm revealed there was stenosis in the juxta-anasto-
mosis site and cephalic venous stenosis. 
Angioplasty was done in anastomose AVF and implantation of venous 
stent in the left cephalic vein.
3. Discussion
3.1 Epidemiology
 From 11th Indonesian Renal Registry 2018, patients with 
Stage 5 CKD show a consistent increase in the number of new and 
active patients.1 Globally, in 2017, there were 697.5 million cases of 
CKD. In 2017, estimated prevalence of CKD was at 9·1% in the world’s 
population.2 It was approximated that the total CKD patients would be 
doubled from 2010 to 2030 will received Renal Replacement Therapy 
(RRT). Asia will have the largest growth in the number of patients 
receiving RRT rising from almost one million patients in 2010 to slightly 
over 2 million patients by 2030.
3.2 Dysfunction of arteriovenous access: Pathophysiology
 There is intricate process that involved in the pathogenesis of 
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of vascular access dysfunction.  The collective pathway is combination 
of neointimal hyperplasia, vascular remodeling inwardly, and impaired 
vessel vasodilation that has consequence of narrowing of the lumen and 
associated with formation of thrombosis. The most site in AVF failure is 
at the perianastomotic region. The pathophysiologic events leading to 
AVF failure was categorized into upstream events and downstream 
events.6,7,8
3.3 Diagnosing AVF Stenosis 
 The reasons for implementing vascular access monitor and 
surveillance routinely, are to find and repair AVF stenosis,.to improve 
AVF access function, to reduced or avert dampen dialysis clearance, and 
also to lower the rate of thrombosis. Physical examination is one of the 
clinical monitoring strategies that ideally done when the patient is not 
on dialysis. This requires minimal training, takes minimal equipment 
and time, is cost-efficient, and readily available. When performed by 
experienced medical staff, physical examination of vascular access has 
high sensitivity and specificity (Table 1).10
 The basis of vascular access surveillance is to better the 




Table 1. Routine AV Access Monitoring by Physical Examination.10
Exam steps
look





Well-developed main venous 
outflow, no irregular/dilated areas 
or aneurysm formations, adequate 
areas of straight vein that can be 
used for 2-needle, rope-ladder 
cannulation
Vessel collapses when arm is 
elevated above head
Low-pitch continuous diastolic 
and systolic
Thrill at the arterial anastomosis 
and throughout the entire outflow 
vein that is easy to compress
Graft (Normal)
Uniform-sized graft in a 
loop or straight 
configuration
No irregular areas or 
aneurysm or seroma 
formations with organized 




Thrill strongest at the 
arterial anastomosis but 
should be felt over entire 
graft and be easy to 
compress
Flow Related Dysfunction or
poor Maturation (Abnormal)
AVF with poor 
maturation—multiple venous 
outflow veins (accessory veins), 
poorly defined cannulation 
areas
AVF:
Stenosis can occur in artery or 
any venous outflow vein
Look for a narrowing of the 
outflow vein, abnormal 
pulsations, or aneurysm 
formations
AVF or AVG:
Dilated neck veins or surface 
collateral veins in the arm or 




Pulse at the site of a stenotic 
lesion—may be water-hammer 
in quality and feel
AVG:
Thrill and/or pulse strong at the 
site of stenotic lesion pulse has 
a water-hammer feel
An AVG with a low intra-access 
blood flow feels mushy
Local area of the graft that feels 
mushy or irregular in shape can 
be a site of aneurysm formation
Flow Related Dysfunction or
poor Maturation (Abnormal)
Infection:




skin ulceration due to poor 
arterial blood flow to the hand
Check nail beds, fingers and 
hand for unusual skin changes 
Aneurysm
Abnormal areas of dilatation 
with overlying skin thinning
Steal syndrome
AVF may have a very strong 
bruit
Infection
Warm or painful to touch, 
swelling
Steal syndrome
Feel bilateral limbs (hands and 
fingers) and compare for the 
access limb to be the 
same as the nonaccess limb
Compare temperature, grip 
strength, and range of motion 
and any complaints of changes 
in sensation or pain
If the access limb has any major 
differences than the nonaccess 
limb, consider steal syndrome
Note, Abbreviations: AVF, arteriovenous fistula; AVG, arteriovenous graft.
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vascular access. Clinical parameter connected with vascular access 
stenosis (Table 2) including indicators on physical examination, high 
arterial and venous pressures at the specified blood flow, impaired 
dialysis clearance without known cause, and exaggerate bleeding after 
needle.withdrawal. Surveillance procedures, with specialized 
equipment, have been considered effectively to find AVF stenosis before 
the grown of a clinical indicator.10
 When routine monitoring suggested a clinically important 
AVF stenosis, the diagnostic approach is required to investigate under-
lying lesion (i.e., venous outflow, anastomosis, arterial inflow,). DUS 
can be helpful to examine vascular access from arterial.anastomosis 
to.peripheral venous section and help deciding the causes of thrombotic 
flow-related complication. Percutaneous arteriography and venography 
can surely image from the anastomosis of AVcaccess to the heartaor 
entire AV access circuit.10
3.4 Upper Extremity DUS for evaluation of AVF dysfunction
 In dysfunction of hemodialysis vascular access, decreased 
blood flow in main finding. DUS evaluation of AVF was performed to 
detect stenosis, flow limitation within AVF, and progression of throm-
bosis.
 
 First evaluation with DUS is using greyscale imaging to 
measure diameter of fistula and stenosis. Significant stenosis is defined 
as narrowing of lumen.>50% compared with normal.vascular 
segments situated upstream from stenosis segment. Continue with color 
andaspectral doppler image in long axis plane, peak systolic velocity 
(PSV)aat anastomose is compared withaPSV that was taken in feeding 
artery 2cm upstream from anastomose. Ratio of PSV taken form anasto-
mose and artery 2 cm upstream, above 3:1 was proposed as present of 
stenosis of more than 50%. A study using PSV above 375cm/s has 
sensitivity of 96% and specificity 76% to detect stenosis over than 50% 
in  AVF. However, because sharp angulation of venous origin at anasto-
mosis, that might increase PSV and simulate a stenosis, any stenosis 
found in anastomosis is advisable to confirm with grayscale imaging. 
There are findings suggested although stenosis is demonstrated, blood 
flow of AVF may be sufficient and still can be used for hemodialysis. 
Beside from anastomosis area, any visible narrowing of 
draining vein found on grayscale image or area of color aliasingiwithin 
the vein may require further assessment with velocity measurements by 
spectral Doppler imaging. The PSV at the narrowingivein is compared 
with the PSV of the vein 2 cm upstream (caudal). PSV ratio of a 
draining vein compared with PSV of vein 2cm upstream above 2:1 is 
proposed as sign of stenosis equal or greater than 50%. An assessment 
of the subclavian vein and ipsilateral internal jugular vein with spectral 
Doppler waveforms can detect signs of central stenosis. Central stenosis 
may be exist even with high flow in  vascular access, lead to arm 
swelling. Multiple abnormalities can be found in a single dysfunctional 
vascular access.11,12
3.5 Treatment of Clinically Significant AV Access Stenosis
 If there was thrombosis occurred or imminent, suggested 
from findings done in monitoring or surveillance, angiographic evalua-
tion is usually recommended. Referral for urgent angiographic can be 
done if access thrombosis is found. Contraindications of angiographic 
procedure are infected access, pulmonary hypertension, surgical 
revision less than 30 days before referral, and presence of right to left 
shunt.9
 Endovascular treatment of AVF stenosis is both safe and 
effective. When performed in dedicated center, has high success rates 
and low complication rates,aand has better of primary and secondary 
patency rate. The Society of Interventional Radiology (SIR) and Kidney 
Disease Outcomes Quality Initiative (K-DOQI) have guidelines in 
angiography procedure for acceptable success and patency rates in AVF. 
Stenosis is regarded as significant if there is more than 50% stenosis of 
diameter vessel, anatomical success is determined when there are less 
than 30% residual stenosis, and functional success is decided if there is 
success using the AVF for HD, or the AVF is mature by DUS examina-
tion.13
 Based on the available evidence, there is an algorithm attempt 
to define practical factors of each individual technology. Figure 4 
outlines the primary steps for salvage management of dysfunctional or 
thrombosed AVF access using percutaneous intervention. Percutaneous 
catheteradirected thrombolysis, and thrombectomy with the Angiojet 
oraother catheters, is management of choice for re-define flow in AVF 
thrombosis. In case of patent but failing circuits, after blood flow has 
been successfully restored, any unmasked oraidentified AVF stenosis 
need to be attend to repair functional adequacy of hemodialysis.14,15
Procedures





Alterations in the pulse, with a weak or resistant pulse, difficult to compress, in the area of stenosis
Abnormal thrill (weak and/or discontinuous) with only a systolic component in the region of stenosis
Abnormal bruit (high pitched with a systolic component in the area of stenosis)
Failure of the fistula to collapse when the arm is elevated (outflow stenosis) and lack of pulse augmentation 
(inflow stenosis)
Excessive collapse of the venous segment upon arm elevation
Aspiration of clots
New difficulty with cannulation when previously not a problem
Inability to achieve the target dialysis blood flow
Prolonged bleeding beyond usual for that patient from the needle puncture sites for 3 consecutive dialysis
sessions
Unexplained (>0.2 units) decrease in the delivered dialysis dose (Kt/V) on a constant dialysis prescription without
prolongation of dialysis duration
Table 2. Clinical Indicators (Signs and Symptoms) Suggesting Underlying Clinically Significant Lesions During Access Monitoring.10
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3.6 Management of Antithrombotic after Venous Stenting
 There is still no consensus or guideline for management 
therapy of antithrombotic after venous stent placement to prevent stent 
thrombosis (ST) or in stent restenosis (ISR). In the post procedural 
setting, anticoagulant and/or antiplatelet are used to reduced the 
ST/ISR and recurrent stent thrombosis. There is wide variability of 
prescribing pattern in choosing antithrombotic regimens and the 
duration of therapy. There is possible benefit of triple therapy 
compared to antiplatelet or dual antiplatelet alone in lowering ST/ISR 
rate, although the comparison of bleeding risk between these 
treatments is not yet been investigate.
 Application of anticoagulant practice in this setting was 
adopted from experience in managing venous thromboembolism with 
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Figure 1. (A-C). A 64-year-old man with stenosis of the arteriovenous fistula demonstrated on venogram followed by balloon angioplasty. 
Venogram (A) shows mild stenosis (white arrow) of the arteriovenous. The sequential ballon angioplasty of the stenotic arteriovenous fistula is 
seen (B). Venogram (C) shows good restoration and flow across the lumen.
Figure 2. (A-D). A 64-year-old man with cephalic venous stenosis demonstrated on venogram. He underwent successful angioplasty and stenting. 
Venogram (A) shows severe stenosis (white arrow). The subsequent venogram (B) shows sequential ballon plasty is seen. The stent is seen 
deployed in of the stenotic cephalic vein (C). Venogram (D) shows the restoration of the lumen.
tendency to choose low molecular weight heparin and vitamin K 
antagonist. The practice ofaantiplatelet agents iseextrapolated from 
experience with implantation of arterial stents. Nevertheless, there is 
difference in underlying mechanism of luminal stenosis that occurs in 
venous stent and arterial stent. Stenosis of venous stents occurs in low 
flow and low shear systems, while stenosis of arterial stents is in high 
flow and high shear systems.16 
 To date there still no guidelines consensus to regulate use of 
anticoagulation after venous stenting. However, a recent study showed 
a consensus that the use anticoagulation is prefer for the first 6–12 
months post venous stenting. For those who have history of multiple 
deep venous thromboses, a lifelong anticoagulation is recommended. 
For practice considering use of anticoagulation and antiplatelet therapy 
after venous stenting was based of experience with arterial stenting. As 
S. Widasmara, et al. Heart Sci J 2021; 2(2): 34-39
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previously described, vessel characteristic and flow hemodynamics 
difference between vein and arterial systems, are factors that 
distinguish underlying pathophysiology.
 A retrospective study showed better stent patency in patient 
take anticoagulant along with antiplatelet versus anticoagulation alone. 
Another retrospective study, measures effectiveness of triple therapy 
(anticoagulant and DAPT) versus DAPT only, exhibit fewer rate of 
ST/ISR in triple therapy group, with similar major bleeding events 
between these groups.17
4. Conclusion
 In treating hemodialysis patient with AVF dysfunction, 
literature strongly support percutaneous salvage over surgery as prefer-
able treatment. The advantages of percutaneous intervention are minor 
discomfort, immediate post-operative use of the AVF, lower infection 
rates, and reduced operating times and days in the hospital. AVF 
dysfunction is still prevalent is patient undergone salvage procedure, 
although several differential percutaneous intervention approach have 
already been established.
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